35. Copiktra

(Verastem Oncology)

Active ingredient: duvelisib
Disease: third-line treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma
Peak sales estimate: $500 million to $850 million
Approved: Sept. 24
Company: Verastem Oncology 

The scoop: Previously jilted by Infinity Pharmaceuticals and AbbVie, Copiktra has seen a rough road to its approval as the first dual inhibitor of PI3K-delta and PI3K-gamma. Verastem licensed the drug from Infinity in 2016 for up to $28 million in milestones and no upfront payment—a small outlay compared to the hundreds of millions in projected sales—and a monthly list price set at $11,800. However, Copiktra does carry a black-box warning for four potentially fatal toxicities—as expected, the company said—and it does represent Verastem’s first commercial outing. To start, the company has rounded up a 50-person oncology sales force, medical affairs and patient advocacy teams plus more than $160 million in cash to help get it to market. There, it will compete with PI3K inhibitors such as Gilead Sciences' first-in-class Zydelig, which brought in $72 million in the first half of this year, and Bayer’s Aliqopa, which received an accelerated approval in follicular lymphoma over a year ago. — Conor Hale 

35. Copiktra

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.